What is central sleep apnea and how can you tell if you have it?
In the US, CSA is estimated to affect less than 1% of adults over 40. It's a sleep disorder that is caused by a brief lack of communication between your brain and the muscles that control your breathing.
CSA is also associated with underlying health conditions such as cardiovascular disease, stroke and primary brain disorders.
As with obstructive sleep apnea, it's important to get a diagnosis if you suspect you might have the condition. Undiagnosed CSA can lead to impaired quality of life, and it can also affect your cardiovascular health.
We've spoken with a sleep scientist and a sleep medicine and pulmonary medicine specialist to find out more about this less common form of sleep apnea.
'CSA is a sleep disorder in which the brain fails to signal the muscles of respiration, primarily the diaphragm, to make an effort to take a breath,' explains Dr Peter G Polos, a sleep medicine and pulmonary medicine specialist at JFK University Medical Center in New Jersey.
'This can stop breathing for a period during the night, and it then spontaneously resumes normal breathing until the next cycle," he adds.
Get instant access to breaking news, the hottest reviews, great deals and helpful tips.
"This can occur many times an hour during sleep.'
Central sleep apnea can affect people of all ages, but it's more common in older adults, and those with certain health conditions. Some lifestyle factors can also increase your risk of developing CSA.
The most common risk factors include:
Dr Carleara Weiss, a sleep scientist and sleep science advisor at Aeroflow Sleep, explains that the main risk factor involves having an underlying medical condition, as this can impact the brain's ability to regulate breathing signals to the respiratory muscles.
'These conditions include cardiovascular diseases," she explains.
This can include "stroke and congestive heart failure, chronic use of narcotic medication or substance abuse that suppresses the central nervous system, and neuromuscular diseases such as Parkinson's disease, myasthenia gravis (a chronic autoimmune condition), and amyotrophic lateral sclerosis (ALS).'
But that's not an exhaustive list. Other conditions, like hypothyroidism and kidney failure can also increase the risk of developing central sleep apnea.
'The most common symptom is pauses of breathing during sleep that are most commonly noted by a bed partner,' says Dr Polos.
'Others include spontaneous awakenings due to shortness of breath, excessive daytime sleepiness, morning headaches and concentration difficulties.'
The most common symptom is pauses of breathing during sleep
Dr Weiss adds that people may also wake during the night gasping for air.
'Other symptoms include mood swings, anxiety, depression, sexual dysfunction, and frequent nighttime awakenings,' she says.
Cheynes-Stokes breathing can be another symptom of central sleep apnea. It's a cyclical breathing pattern that is characterised by periods of increase and decrease in breathing depth and periods of apnea (where there is a momentary pause in breathing).
'This pattern of breathing is often seen in people who have heart failure and other conditions that can affect the brain's ability to regulate breathing,' Dr Weiss adds.
If you have any concerns that you may have signs of this sleep disorder, seeking a diagnosis is a priority.
'The first step is to see a sleep physician who will take a detailed history, review medication and carry out a physical examination,' explains Dr Polos. 'In the end, an overnight sleep study is often the next step to secure the diagnosis.'
'It is important to make this diagnosis because the consequences such as lower oxygen during sleep, can produce strain on the heart and lead to cardiac complications,' he adds.
'Untreated CSA is associated with fatigue and driving risk, concentration decline, and poor quality of life.'
Additionally, others could notice changes in your sleep and your health before you realise you have any symptoms.
'If you or your partner have any questions or concerns about the quality or quantity of your sleep, and if those around you observe changes in your mood, energy, performance or concentration, seek advice from your primary care physician or a sleep specialist,' Dr Polos advises.
Central sleep apnea treatments can help to improve the quality and quantity of your sleep and improve daytime symptoms. Here are some of the ways CSA can be treated.
If you have mild symptoms of CSA, lifestyle changes might be all you need to do in terms of treatment.
These include trying to lose weight if you are overweight, keeping active and exercising regularly, and practising good sleep hygiene.
For example, making sure your bedroom is dark and quiet and going to bed and waking up at the same time each day. You may find sleeping on your side is helpful too.
Making lifestyle changes along with taking prescribed medication may be enough to treat mild to moderate central sleep apnea.
'The first step should be to address any underlying medical conditions,' explains Dr Polos. 'For example, if the patient has heart failure, this needs to be medically managed, which by itself may correct the CSA.
'In addition, reducing or discontinuing any drug that may contribute to CSA must also be considered,' he adds.
Treatments that can help to regulate abnormal breathing patterns such as PAP therapy are usually considered after lifestyle changes and medication have been tried, but symptoms of CSA continue.
'The primary mode of treatment is positive airway pressure,' says Dr Polos. 'The modalities can include bilevel positive airway pressure (BiPAP) or adaptive servo-ventilation (AS)."
"These are specialised methods of delivering positive pressure to the airways in CSA.'
To treat CSA, traditional continuous positive airway pressure (CPAP) is often used, Dr Weiss explains. 'This provides the same pressure during breathing or a BiPAP can provide different pressure levels during inhalation and exhalation.
'Some patients may also qualify for surgery or phrenic nerve stimulation,' she adds, 'and in other cases, a combined therapy of PAP therapy plus medication may be recommended.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Tom's Guide
20 hours ago
- Tom's Guide
What is central sleep apnea and how can you tell if you have it?
Central sleep apnea (CSA) is a sleep disorder that is less common than obstructive sleep apnea, but it does have some similarities. In the US, CSA is estimated to affect less than 1% of adults over 40. It's a sleep disorder that is caused by a brief lack of communication between your brain and the muscles that control your breathing. CSA is also associated with underlying health conditions such as cardiovascular disease, stroke and primary brain disorders. As with obstructive sleep apnea, it's important to get a diagnosis if you suspect you might have the condition. Undiagnosed CSA can lead to impaired quality of life, and it can also affect your cardiovascular health. We've spoken with a sleep scientist and a sleep medicine and pulmonary medicine specialist to find out more about this less common form of sleep apnea. 'CSA is a sleep disorder in which the brain fails to signal the muscles of respiration, primarily the diaphragm, to make an effort to take a breath,' explains Dr Peter G Polos, a sleep medicine and pulmonary medicine specialist at JFK University Medical Center in New Jersey. 'This can stop breathing for a period during the night, and it then spontaneously resumes normal breathing until the next cycle," he adds. Get instant access to breaking news, the hottest reviews, great deals and helpful tips. "This can occur many times an hour during sleep.' Central sleep apnea can affect people of all ages, but it's more common in older adults, and those with certain health conditions. Some lifestyle factors can also increase your risk of developing CSA. The most common risk factors include: Dr Carleara Weiss, a sleep scientist and sleep science advisor at Aeroflow Sleep, explains that the main risk factor involves having an underlying medical condition, as this can impact the brain's ability to regulate breathing signals to the respiratory muscles. 'These conditions include cardiovascular diseases," she explains. This can include "stroke and congestive heart failure, chronic use of narcotic medication or substance abuse that suppresses the central nervous system, and neuromuscular diseases such as Parkinson's disease, myasthenia gravis (a chronic autoimmune condition), and amyotrophic lateral sclerosis (ALS).' But that's not an exhaustive list. Other conditions, like hypothyroidism and kidney failure can also increase the risk of developing central sleep apnea. 'The most common symptom is pauses of breathing during sleep that are most commonly noted by a bed partner,' says Dr Polos. 'Others include spontaneous awakenings due to shortness of breath, excessive daytime sleepiness, morning headaches and concentration difficulties.' The most common symptom is pauses of breathing during sleep Dr Weiss adds that people may also wake during the night gasping for air. 'Other symptoms include mood swings, anxiety, depression, sexual dysfunction, and frequent nighttime awakenings,' she says. Cheynes-Stokes breathing can be another symptom of central sleep apnea. It's a cyclical breathing pattern that is characterised by periods of increase and decrease in breathing depth and periods of apnea (where there is a momentary pause in breathing). 'This pattern of breathing is often seen in people who have heart failure and other conditions that can affect the brain's ability to regulate breathing,' Dr Weiss adds. If you have any concerns that you may have signs of this sleep disorder, seeking a diagnosis is a priority. 'The first step is to see a sleep physician who will take a detailed history, review medication and carry out a physical examination,' explains Dr Polos. 'In the end, an overnight sleep study is often the next step to secure the diagnosis.' 'It is important to make this diagnosis because the consequences such as lower oxygen during sleep, can produce strain on the heart and lead to cardiac complications,' he adds. 'Untreated CSA is associated with fatigue and driving risk, concentration decline, and poor quality of life.' Additionally, others could notice changes in your sleep and your health before you realise you have any symptoms. 'If you or your partner have any questions or concerns about the quality or quantity of your sleep, and if those around you observe changes in your mood, energy, performance or concentration, seek advice from your primary care physician or a sleep specialist,' Dr Polos advises. Central sleep apnea treatments can help to improve the quality and quantity of your sleep and improve daytime symptoms. Here are some of the ways CSA can be treated. If you have mild symptoms of CSA, lifestyle changes might be all you need to do in terms of treatment. These include trying to lose weight if you are overweight, keeping active and exercising regularly, and practising good sleep hygiene. For example, making sure your bedroom is dark and quiet and going to bed and waking up at the same time each day. You may find sleeping on your side is helpful too. Making lifestyle changes along with taking prescribed medication may be enough to treat mild to moderate central sleep apnea. 'The first step should be to address any underlying medical conditions,' explains Dr Polos. 'For example, if the patient has heart failure, this needs to be medically managed, which by itself may correct the CSA. 'In addition, reducing or discontinuing any drug that may contribute to CSA must also be considered,' he adds. Treatments that can help to regulate abnormal breathing patterns such as PAP therapy are usually considered after lifestyle changes and medication have been tried, but symptoms of CSA continue. 'The primary mode of treatment is positive airway pressure,' says Dr Polos. 'The modalities can include bilevel positive airway pressure (BiPAP) or adaptive servo-ventilation (AS)." "These are specialised methods of delivering positive pressure to the airways in CSA.' To treat CSA, traditional continuous positive airway pressure (CPAP) is often used, Dr Weiss explains. 'This provides the same pressure during breathing or a BiPAP can provide different pressure levels during inhalation and exhalation. 'Some patients may also qualify for surgery or phrenic nerve stimulation,' she adds, 'and in other cases, a combined therapy of PAP therapy plus medication may be recommended.'
Health Line
21 hours ago
- Health Line
Can You Lose Medicare Coverage?
Medicare coverage is a lifelong benefit for individuals who meet eligibility criteria. However, there are certain situations where a person may have their coverage canceled. To be eligible for Medicare, the federal health insurance program for older adults in the United States, you need to be 65 years of age or older. If you're younger than 65 years old, you may qualify for Medicare if you: have disability and collect Social Security Disability Insurance have end stage renal disease (ESRD) have amyotrophic lateral sclerosis (ALS) If you meet the eligibility requirements for Medicare, you have a right to coverage for the rest of your life. However, it's possible for your coverage to be canceled or discontinued. In this article, we discuss when this might occur and how to reenroll. Why might you lose Medicare coverage? A person may lose their Medicare coverage if they: stop paying their plan's premiums move out of their plan's service area no longer meet the eligibility criteria for the plan Nonpayment of Medicare premiums If you stop paying your monthly premiums, Medicare may terminate your coverage. Individuals enrolled in Original Medicare may have premium payments for Part A and Part B. Generally, there is a grace period of a couple of months after a person stops paying their premium. During this time, you can get caught up on your payments. However, if you don't resume them, Medicare will disenroll you from your coverage. If you're enrolled in a Medicare Advantage (Part C) or Part D plan, you'll also need to continue paying your monthly premiums or risk termination of your coverage. Moving out of a plan's service area If you move your permanent residence outside of your plan's service area, it may affect your coverage. Original Medicare coverage works anywhere in the United States. If you move abroad, you can stay enrolled in Medicare, but it won't cover any healthcare services you receive. Likewise, if you're incarcerated, you can keep your Original Medicare coverage, but it won't be applied toward any of your healthcare costs, which will be covered by the penal institution. Medicare Advantage plans work a bit differently. These plans have regional service areas, and your home address determines which plans you're eligible for. If you move out of your county or state, it's possible that you'll no longer be in your plan's service area. If you have a Medicare Advantage plan and become incarcerated, the plan will consider you outside its service area and disenroll you. If this happens, you may be disenrolled from the plan. No longer meeting eligibility criteria If you're eligible for Social Security Disability Insurance (SSDI), you're also eligible for Medicare. Eligibility involves having a condition that: prevents you from working at the substantial gainful activity (SGA) level prevents you from working at the same level you once did is expected to last for at least a year or be fatal If you no longer meet the eligibility requirements for disability with the Social Security Administration, and you're younger than 65 years old, your Medicare coverage may be discontinued. However, if you have a qualifying disability but end up returning to work, you won't automatically lose your Medicare coverage, provided your disability persists. If you qualify for Medicare due to ESRD, your Medicare coverage will end 12 months after you stop receiving dialysis and 36 months after a successful kidney transplant. Depending on why you lost Medicare coverage, you can likely reinstate it. If you are disenrolled from Original Medicare, a Medicare Advantage plan, or a Part D plan due to nonpayment of the plan's premium, you'll have to wait until the Medicare open enrollment period to sign back up. However, if you go without Medicare coverage for an extended time, you may be responsible for paying late enrollment penalties after you do enroll. People who lost coverage due to leaving their plan's service area may be able to avoid late enrollment penalties by qualifying for a special enrollment period (SEP). SEPs allow people to enroll in coverage outside of traditional enrollment periods. If you have questions about reenrolling in Medicare after losing coverage, consider speaking with a Medicare representative about your situation or contacting your local State Health Insurance Assistance Program (SHIP). The information on this website may assist you in making personal decisions about insurance, but it is not intended to provide advice regarding the purchase or use of any insurance or insurance products. Healthline Media does not transact the business of insurance in any manner and is not licensed as an insurance company or producer in any U.S. jurisdiction. Healthline Media does not recommend or endorse any third parties that may transact the business of insurance.
Medscape
a day ago
- Medscape
Lessons for Parkinson's From MS, and Vice Versa
This transcript has been edited for clarity. Indu Subramanian, MD: Hi, everyone. Welcome to Medscape. I'm so excited to have my friend and colleague, Prof Lorraine Kalia, join us today to talk about a very cool topic: what we can learn from multiple sclerosis (MS) studies and therapies, and how we can maybe translate that to some of the problems that we've been having in the Parkinson's world. Prof Lorraine Kalia is a clinical scientist at the Krembil Institute. She's also an amazing neurologist at the University of Toronto, which is my alma mater. Welcome, Lorraine. Lorraine V. Kalia, MD, PhD: Hi, Indu. Thanks for having me. Meeting of MS and PD Minds Subramanian: My name is Dr Indu Subramanian. I'm based at UCLA. Maybe we can get right into this. You had this very cool meeting in November 2022, and you had experts in the MS world as well as the Parkinson's disease world. Tell us a little bit about what inspired that meeting in the first place. Kalia: It's a bit of a personal story, actually. I might date myself a little bit, but I was a medical student during the time of the natalizumab development. At that time, I thought I was going to be an MS neurologist. Even back then, they already had a couple of disease-modifying therapies for MS and I thought, You know what, I think MS is good. I think they're in good shape. As a scientist with an understanding of the biology behind disease, it was clear to me that there still was a large amount of work needing to be done in Parkinson's disease because that's obviously how we translate things into having disease-modifying therapies. That was part of the reason — not the only reason — why I shifted into the movement disorder space. Fast-forward many years later: I often give talks around the lack of disease-modifying therapies for Parkinson's disease by introducing MS. Sometimes when you ask why we don't have a disease-modifying therapy for Parkinson's, people throw up their hands and say, "Well, you know, neurologic diseases are complicated." I'll often use the MS example to demonstrate that actually there is much that can be done in the neurologic space and there's been a lot of successes in MS. I was once giving this talk, and as a consequence of this talk, had a conversation with Parkinson Canada who thought, wow, that's an interesting idea around MS being so successful and PD lagging behind. We came up with the idea of having a meeting in Toronto. We obviously have very strong Parkinson's researchers in Toronto, but also a very strong MS team at the Saint Michael's Hospital. I collaborated with a colleague — actually, we were residents together — to bring world experts to Toronto to sit around a table, which is what we did, and talk about where we are in MS and where we are in Parkinson's disease. We were looking for common ground but also looking to see what is different and how we might think about things differently that might have led to the different paths that we've experienced in our fields. Lessons From MS Subramanian: What do you think some take-home messages for the clinician would be from that discussion? I think it was a very cool paper. Kalia: Maybe the take-home messages is it's complicated, which is not as simple as I had hoped. I hoped that we'd come back with clear messages of what we really need to do with Parkinson's. I think we found common ground for one thing. I think it's fair to say that MS has done remarkably well at treating inflammation. All of their drugs are based on that, and they will recognize that they have challenges in terms of treating the neurodegenerative part of their condition. Now that we increasingly recognize that inflammation is a part of Parkinson's disease and there's increased work around the immune basis to the disease, I think we are going to be able to take advantage of what MS has done and learn to hopefully make advances that way. For anybody who's learned about MS , its successes have hanged heavily on its neuroimaging biomarkers of MRI. Of course, biomarkers are needed for the development of Parkinson's disease , and perhaps more work into the neuroimaging piece as well as the biospecimen biomarkers is key to starting to be able to have different kinds of outcome measures. Not the clinical outcome measures that we're using right now in basically all of our clinical trials, but to have early biomarker outcome measures that will help to inform us for our later clinical trials. The other commonality between the two is this concept of earlier disease. We have our prodromal Parkinson's disease and MS has their radiologically isolated syndrome. Up until now, logically, it has made sense to us that we should treat earlier in Parkinson's disease, and that will likely give us better successes. In the MS space, there's actually proof of that. They have clinical trials showing the benefit of treating people in the radiologically isolated syndrome state. While in Parkinson's disease, it has been theoretical and seems to make sense to all of us, we don't have any hard proof to say that treating earlier is better, whereas in MS they have already demonstrated that. I think this then provides us with actual proof in the pudding that that approach really does have implications for disease progression. PD Ahead of MS for Lifestyle Subramanian: Absolutely. I think both diseases in many ways have revolutionized since back in the day when we were in training. The MS models have really come a long way, with many patients doing very well for a long time. I think we have to really take a look at where our feelings are and how we can do better. I'm excited just about the concept of identifying people early and then getting people who may be even at risk for developing Parkinson's into lifestyle measures and wellness choices. I think MS has done a great job of that as well. Can you speak a little bit about that from your own perspective? Kalia: I don't think it came out in the paper, but it came out in our discussions that as a field and as a patient population, there's probably been more embrace of lifestyle measures and physical activity in Parkinson's, which I think is kudos to us in Parkinson's disease. Maybe it's in part because in MS they have these drugs that came through one after another after another, and there's this heavy pharma management of MS that they haven't had to explore the lifestyle assets. There's a large amount that MS has to learn from Parkinson's disease, in terms of putting in place so many of the things that we discuss in Parkinson's, whether it be diet, sleep, stress or mindfulness — all of these things. I think that in Parkinson's, we're further ahead. Subramanian: Absolutely. I agree with you. I'm excited to learn from these other disease states that we train under in residency. We see these patients and we can open our minds to looking at different lenses, for sure. Thank you so much for spending the time and chatting about this. Kudos to you for having that meeting. It sounds like a great opportunity to bring great minds together. Kalia: Yes. Hopefully, we can do more of this in the future. Subramanian: Go Canada. Thank you for joining us, everyone.
